Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beckman Coulter Ponders Inverness’ “Superior” Bid For Biosite

This article was originally published in The Gray Sheet

Executive Summary

Beckman Coulter has until May 2 to engage in a bidding war with Inverness Medical Innovations for cardiac diagnostic maker Biosite

You may also be interested in...



Beckman Coulter sweetens Biosite bid to $1.67 billion

Biosite suitor Inverness Medical Innovations is weighing its next move after its unsolicited $90-per-share offer for heart test maker Biosite is matched by Beckman Coulter. Biosite initially had agreed to be acquired by Beckman for $85 per share, or $1.55 billion, on March 24. However, Biosite subsequently determined that Inverness' April 4 bid was superior to the initial Beckman deal. An amended merger agreement between Biosite and Beckman announced May 2 is worth $1.67 billion, according to Biosite. Under the revised deal, Beckman's $90-per-share cash tender offer will be open until May 15. "In light of this development we are evaluating our alternatives," Inverness CEO Ron Zwanziger said during the firm's Q1 earnings call May 2 (1"The Gray Sheet" April 30, 2007, p. 10)...

Beckman Coulter sweetens Biosite bid to $1.67 billion

Biosite suitor Inverness Medical Innovations is weighing its next move after its unsolicited $90-per-share offer for heart test maker Biosite is matched by Beckman Coulter. Biosite initially had agreed to be acquired by Beckman for $85 per share, or $1.55 billion, on March 24. However, Biosite subsequently determined that Inverness' April 4 bid was superior to the initial Beckman deal. An amended merger agreement between Biosite and Beckman announced May 2 is worth $1.67 billion, according to Biosite. Under the revised deal, Beckman's $90-per-share cash tender offer will be open until May 15. "In light of this development we are evaluating our alternatives," Inverness CEO Ron Zwanziger said during the firm's Q1 earnings call May 2 (1"The Gray Sheet" April 30, 2007, p. 10)...

Biosite Agrees To Inverness Merger Talks While Beckman Waits At The Altar

Heart test maker Biosite has agreed to merger talks with Inverness Medical Innovations despite its previous agreement to be acquired by Beckman Coulter for $1.55 billion

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel